Letters by company
PHI Group Inc
4 letters discussing PHIG. Everything written about it on this site is on its ticker page.
- Cedar Creek Partners Cedar Creek Partners 2026 Second Quarter Results Cedar Creek Partners increased expert-market exposure while building positions in companies affected by SEC Rule 15c2-11, arguing that trading restrictions create mispricings. It detailed cash-backed Harbor Diversified, Exco’s reserve development, PHI tender concerns, Solitron’s strategic review, Queen City’s ranch sale and cheaply valued community banks. Q2 ‘26 ENDI $125MEXCE $1.2BHRBR $129M
- Cedar Creek Partners Cedar Creek Partners 2026 First Quarter Results Cedar Creek Partners added Harbor Diversified after its Air Wisconsin asset sale and continued allocating to expert-market stocks, citing discounts to estimated asset values and earnings. The fund sold MetroCity Bankshares after the First IC transaction, built Steele Bancorp, and retained Solitron Devices amid its strategic-alternatives review and defense-production backlog. 2026 First Quarter ENDI $125MEXCE $1.2BHRBR $129M
- Cedar Creek Partners Cedar Creek Partners 2025 Results Cedar Creek Partners redeployed cash after exits in PharmChem, Propel Media and First IC, while building major positions in Exco Resources and PHI Group. The fund argued that Exco's production growth and hedging support its upside, and that Solitron Devices and ENDI are positioned for improving earnings and asset growth. 2025 ENDI $125MEXCE $1.2BPHIG $760M
- Cedar Creek Partners Cedar Creek Partners 2025 Third Quarter Results Cedar Creek Partners sold PharmChem following its buyout and exited Citizens Bancshares, redirecting much of the proceeds into PHI Group and other undervalued community banks. The portfolio increased its expert-market exposure, with substantial positions in Propel Media, PHI Group and First IC, while Solitron’s order backlog and ENDI’s asset-management growth supported the investment cases. Q3 ‘25 CZBS $115MENDI $125MPHIG $760M
